A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

• Status: Completed
• Trial end date: 2006-11-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Pentostatin

Criteria

Inclusion Criteria:

• Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.

• No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.

• Life expectancy of at least 12 weeks.

• Performance status equal to or less than Zubrod 2.

• Signed informed consent.

• Patients with measurable disease.

• Age at least 16 years.

• Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.

• Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.

• Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

Exclusion Criteria:

• No serious intercurrent illness.

• Adequate contraception (if applicable).

• NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.

• NO experimental clinical trial within 3 weeks of study entry.

• NO patients with active CNS disease.

• Full recovery from any prior surgical treatment.

• NO active active infections.